Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

874 ARTÍCULOS , VIENDO DEL 376 AL 390

Sustained Clinical Benefit of Adaptive Deep Brain Stimulation in Parkinson's Disease Using Gamma Oscillations: A Case Report

Cernera S, Oehrn CR, Hammer LH, Shcherbakova M, Yao J, Hahn A, Wang S, Ostrem JL, Little S, Starr PA.

Mov Disord. 2025 Feb;40(2):345-350. doi: 10.1002/mds.30076. Epub 2024 Dec 4.

Clinical Outcome Assessments for Spasticity: Review, Critique, and Recommendations

Gal O, Baude M, Deltombe T, Esquenazi A, Gracies JM, Hoskovcova M, Rodriguez-Blazquez C, Rosales R, Satkunam L, Wissel J, Mestre T, Sánchez-Ferro Á, Skorvanek M, Tosin MHS, Jech R; members of the MDS Clinical Outcome Assessments Scientific Evaluation Committee and MDS Spasticity Study group.

Mov Disord. 2025 Jan;40(1):22-43. doi: 10.1002/mds.30062. Epub 2024 Dec 4.

Sex Differences in Parkinson's Disease: A Narrative Review

Cattaneo C, Pagonabarraga J.

Neurol Ther. 2025 Feb;14(1):57-70. doi: 10.1007/s40120-024-00687-6. Epub 2024 Dec 4.

Artificial intelligence for identification of candidates for device-aided therapy in Parkinson's disease: DELIST-PD study

Freire-Álvarez E, Ramírez IL, García-Ramos R, Carrillo F, Santos-García D, Gómez-Esteban JC, Martínez-Castrillo JC, Martínez-Torres I, Madrid-Navarro CJ, Pérez-Navarro MJ, Valero-García F, Vives-Pastor B, Muñoz-Delgado L, Tijero B, Martínez CM, Valls JM, Aler R, Galván IM, Escamilla-Sevilla F.

Comput Biol Med. 2025 Feb;185:109504. doi: 10.1016/j.compbiomed.2024.109504. Epub 2024 Dec 4.

Safety of adipose-derived stromal vascular fraction cells to treat Parkinson's disease

Carstens M, Martínez-Cerrato J, Garcia L, Rivera B, Bertram K.

Parkinsonism Relat Disord. 2025 Mar;132:107214. doi: 10.1016/j.parkreldis.2024.107214. Epub 2024 Nov 28.

In PD, Non-Invasive Trans-Spinal Magnetic Stimulation Enhances the Effect of Transcranial Magnetic Stimulation on Axial Motor Symptoms: A Double-Blind Randomized Clinical Trial

Khedr EM, Haridy NA, Korayem MA, Tawfik AM, Hamed AA.

Neurorehabil Neural Repair. 2025 Feb;39(2):126-137. doi: 10.1177/15459683241300547. Epub 2024 Dec 11.

Bilateral Lesions in Parkinson's Disease: Gaps and Controversies

Rodriguez-Oroz MC, Martínez-Fernández R, Lipsman N, Horisawa S, Moro E.

Mov Disord. 2025 Feb;40(2):231-240. doi: 10.1002/mds.30090. Epub 2024 Dec 27.

The centenarian blueprint: lessons in defying Parkinson's disease

Bhidayasiri R, Aiba I, Nomoto M.

J Neural Transm (Vienna). 2025 Mar;132(3):331-339. doi: 10.1007/s00702-024-02875-y. Epub 2024 Dec 27.

Statins as potential disease-modifying therapy of Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis

Gonçalves OR, Nascimento AB, Soares VG, Abraham D, de Almeida Monteiro G, Freitas JLR, da Cunha Monteiro Ribeiro JP, Ribeiro BL, de Oliveira JVA, Dos Santos MAR, Telles JPM, Sekeff-Sallem F, Almeida KJ.

Acta Neurol Belg. 2025 Aug;125(4):915-922. doi: 10.1007/s13760-024-02709-4. Epub 2024 Dec 30.

The complexities in the differential diagnosis of restless legs syndrome (Willis-Ekbom disease)

Poplawska-Domaszewicz K, Rota S, Qamar MA, Chaudhuri KR.

Expert Rev Neurother. 2025 Feb;25(2):157-173. doi: 10.1080/14737175.2025.2450639. Epub 2025 Jan 14.

Parkinsonism and Bilateral Facial Palsy after Chimeric Antigen Receptor T-Cell Therapy

Wu AS, Hophing L, Gosse P, Motamed M, Bhella SD, Stewart K, Fasano A.

Mov Disord Clin Pract. 2025 Mar;12(3):371-374. doi: 10.1002/mdc3.14335. Epub 2025 Jan 9.

Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial

Ferreira JJ, Rascol O, Stocchi F, Antonini A, Moreira J, Castilla-Fernández G, Rocha JF, Holenz J, Poewe W; Epsilon Study investigators.

Eur J Neurol. 2025 Jan;32(1):e16420. doi: 10.1111/ene.16420.

A smart tool for non expert clinicians for the dissemination of the MDS criteria for progressive supranuclear palsy

Picillo M, Abate F, Canoro V, Tepedino MF, Barone P, Erro R.

Neurol Sci. 2025 May;46(5):1959-1964. doi: 10.1007/s10072-025-07996-0. Epub 2025 Jan 11.

Prospective Multicenter Evaluation of the MDS "Suggestive of PSP" Diagnostic Criteria

Quattrone A, Franzmeier N, Levin J, Petzold GC, Spottke A, Brosseron F, Falkenburger B, Prudlo J, Gasser T; DESCRIBE‐PSP Group, The ProPSP Group; Höglinger GU.

Mov Disord. 2025 Mar;40(3):526-536. doi: 10.1002/mds.30112. Epub 2025 Jan 10.

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Seppi K, Monnet A, Shariati N, Ricci B, Rutten-Jacobs L, Respondek G, Kustermann T, Taylor KI, Trundell D, Fontoura P, Doody R, Svoboda H, Bonni A; PADOVA Investigators and Prasinezumab Study Group.

Parkinsonism Relat Disord. 2025 Mar;132:107257. doi: 10.1016/j.parkreldis.2024.107257. Epub 2024 Dec 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias